Opening book details…
About this Medicine article
Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer by Onder Tonyali; Anatolian Society of Medical Oncology (ASMO); Ugur Coskun; Nur Sener; Mevlude Inanc; Tulay Akman; Berna Oksuzoglu; Nuriye Yildirim Ozdemir; Dogan Yazilitas; Mustafa Benekli; Aytug Uner; Deniz Yamac; Umut Demirci; Ramazan Yildiz; Halit Karaca; Olcun Umit Unal; Oznur Bal; Mahmut Gumus; Suleyman Buyukberber is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Onder Tonyali; Anatolian Society of Medical Oncology (ASMO); Ugur Coskun; Nur Sener; Mevlude Inanc; Tulay Akman; Berna Oksuzoglu; Nuriye Yildirim Ozdemir; Dogan Yazilitas; Mustafa Benekli; Aytug Uner; Deniz Yamac; Umut Demirci; Ramazan Yildiz; Halit Karaca; Olcun Umit Unal; Oznur Bal; Mahmut Gumus; Suleyman Buyukberber
- Publisher
- Springer Science and Business Media LLC
- Published
- 2012
- Language
- EN
- Field
- Medicine (Health Sciences)